MSK-IMPACT 410 (IMPACT410)
Overview
Targeted (410 cancer genes) sequencing of various tumor types via MSK-IMPACT on Illumina HiSeq sequencers — canonical cBioPortal gene panel IMPACT410.
Used by
- PMID:37078708 — one of the panel eras used to profile 132 adults with nodal PTCL at MSK; identified TP53 mutations (16%, 21/132) as inferior-PFS markers and CDKN2A deletions (7%) as inferior-OS markers PMID:37078708.
- PMID:37315267 — MSK-IMPACT (410–505 genes) was used in 40% of 61 extremity rhabdomyosarcoma patients; identified MED12 alterations, CDK4 amplifications, and CDKN2A deletions as recurrent ARMS events, with mutually exclusive CDK4 amp / CDKN2A del correlating with poor OS (P=.02) PMID:37315267.
- PMID:37591896 — one of the MSK-IMPACT panel versions used for 233 resected NSCLC brain metastases plus matched primaries and extracranial mets PMID:37591896.
- PMID:39214094 — IMPACT410 was one of the MSK-IMPACT panel generations (n=438 patients) used in the 397-patient sequenced subset of 1,360 resected PDAC cases at MSK; contributed to the allele-specific KRAS profiling showing KRASG12R enrichment in stage I disease and improved OS vs KRASG12D PMID:39214094.
- PMID:39753968 — IMPACT410 was one of four panel generations (n=438 patients) used in the 2,336-patient MSK PDAC cohort; allele-specific copy number inferred with FACETS; KRAS mutant-allele dosage gains correlated with shorter OS independent of whole-genome doubling PMID:39753968.
- IMPACT410 (MSK-IMPACT 410-gene panel) used with matched normal DNA at median 600x coverage (CLIA-approved) to profile 151 advanced head and neck tumors; enabled actionable finding detection in 21% of cases and guided therapy in 14% of patients PMID:27442865
- IMPACT410 used as the targeted sequencing assay in a prospective 161-patient GCT validation cohort; confirmed TP53 alteration exclusivity to cisplatin-resistant tumors and identified RAC1 hotspot mutations at 5% incidence PMID:27646943
- Deployed MSK-IMPACT410 panel for expanded targeted sequencing in the clinical sequencing program PMID:28336552
- Used to sequence 19 anaplastic oligodendroglioma tumors from the MSK HDC-ASCT trial (odg_msk_2017), confirming canonical IDH1/TERT/CIC/FUBP1 signatures in 1p/19q-codeleted cases PMID:28472509
- 410-gene panel used in 74% (8,136/10,945) of the MSK-IMPACT prospective cohort; hybrid-capture, mean depth 718x, with patient-matched normal blood DNA for 98% of cases PMID:28481359
- Used alongside IMPACT341 to sequence 105 NMIBC tumors from the blca_nmibc_2017 cohort; identified ARID1A mutations as the only gene significantly associated with BCG recurrence PMID:28583311
- 410-gene version of MSK-IMPACT applied to a subset of 295 metastatic EGC patients in the MSKCC prospective sequencing cohort PMID:29122777
- Used in 911 of 1,134 prospectively sequenced COADREAD cases at MSKCC (mean coverage 747×) as the primary panel in the MSK-IMPACT CRC landscape study PMID:29316426
- Applied to 164 of 240 advanced NSCLC patients treated with anti-PD-(L)1 therapy; validated that targeted-panel TMB estimates correlate with WES (Spearman r=0.86) and predict durable clinical benefit PMID:29337640
- Used in 88 of 106 centrally sequenced SUMMIT basket-trial patients for ERBB2/ERBB3-mutant solid tumors (mean coverage 738×) PMID:29420467
Notes
- The 410-gene panel is the middle generation of MSK-IMPACT, intermediate between IMPACT341 and IMPACT468 PMID:37078708.
Sources
- PMID:37078708
- PMID:37315267
- PMID:37591896
- PMID:39214094
- PMID:39753968
schema/ontology/gene_panels.json(genePanelId: IMPACT410)
This page was processed by crosslinker on 2026-05-04. - PMID:27442865
This page was processed by wiki-cli on 2026-05-14. - PMID:27646943
This page was processed by entity-page-writer on 2026-05-15. - PMID:28336552
This page was processed by wiki-cli on 2026-05-14. - PMID:28472509
This page was processed by entity-page-writer on 2026-05-15. - PMID:28481359
This page was processed by entity-page-writer on 2026-05-15. - PMID:28583311
This page was processed by entity-page-writer on 2026-05-15. - PMID:29122777
This page was processed by entity-page-writer on 2026-05-15. - PMID:29316426
This page was processed by wiki-cli on 2026-05-15. - PMID:29337640
This page was processed by wiki-cli on 2026-05-15. - PMID:29420467
This page was processed by wiki-cli on 2026-05-15.